76 vets, 34 nurses and 7 other practice staff took part in the survey, which was conducted at the VetsNow ECC Virtual Congress. Participants were asked a number of questions on antibiotic resistance and UTI management.
47% of vets said they currently feel confident prescribing antibiotics for suspected UTIs in the absence of culture and sensitivity results. However, 84% would be confident if they were able to use a rapid in-house sensitivity test.
77% of the participants said they were concerned about the increasing emergence of antimicrobial resistance.
Rachel Kirkby MRCVS, Business Development Director, said: "Antibiotic resistance is a huge threat to both human and animal healthcare across the world. We all need to work together to address it, and at Test and Treat we want to make it easier for vets in practice to do their bit by prescribing antibiotics according to best practice."
Test and Treat says the problem is that while many vets are keen to tackle resistance, it is not always easy to avoid empirical prescribing in practice. Of the vets surveyed, 65% reported that they are typically not able to obtain an accurate clinical diagnosis prior to prescribing antimicrobial therapy.
Rachel said: “It can be frustrating for vets to have to prescribe empirically when they don’t have any information on antibiotic sensitivity. But logistical constraints often mean that it’s not practical to send samples off to the lab.”
Test and Treat's U-Treat system consists of two rapid tests: a 5-minute assay that can confirm the presence of infection and a 30-minute assay that evaluates antibiotic sensitivity. With this diagnostic tool, vets can therefore select and prescribe the most appropriate antibiotic within an hour.
Rachel said: "Since you get results so quickly, you can use the test while the owner waits – or, in the current situation, more likely goes for a walk and comes back. This means that vets can get their patients started on the most appropriate treatment right away.”
U-Treat is currently validated for use in dogs and cats, but company says it is also looking to license it in rabbits and human healthcare.
To find out more about U-Treat, contact Test and Treat’s National Sales Manager Jo Nickerson on Jo.Nickerson@tandtreat.com or visit http://www.tandtreat.com.
The patient-side test identifies urinary tract infection (UTI) and the best antibiotics to treat the condition, with the results produced in minutes.
Test and Treat says the new test means that vets will no longer have to treat empirically while a urine sample is sent to an external laboratory. Nor will you have to risk delaying treatment until the results are received.
In addition, the company says that the test will help support the responsible use of antibiotics, which is particularly important given that Enterococci strains identified in canine urinary infections have been found to be resistant to three or more antimicrobials1.
U-treat is a two-part test. The first part of the test detects the presence of a urinary infection. The second part of the test looks at antibiotic susceptibility, showing the best choice of antibiotic and identifying those that won't work due to antimicrobial resistance.
Using the principles of bioluminescence, U-Treat removes host cell ATP before lysing bacterial cell walls to release bacterial ATP, which is then detected using a luminometer. The initial detection of infection test takes five minutes and the susceptibility test takes 30 minutes.
Clinical evaluation of the test in cats and dogs was carried out at University of Tennessee in conjunction with Prof. David Bemis of Cornell University. The company says U-Treat demonstrated high levels of sensitivity (97.1%) and specificity (92%), compared to lab tests.
The test is currently validated for use in dogs and cats and is being investigated for use in horses. While the test will launch first in the veterinary world, it also has scope to cross over into human medicine where there is potential to use it in general practice, paediatric and geriatric care.
Ron Turner, CEO and Scientific Director of Test and Treat said: "We've already sent our first orders to the US and have being talking at veterinary conferences about the technology - so we know vets are keen to get access to this new diagnostic test. Fast, reliable and accurate results mean that it's easier to put together a rational treatment plan that they can be very confident will work because they have the evidence."
Test and Treat is based near Newmarket in Suffolk and orders for the test are now being taken from veterinary practices in the UK. Full training will be given and the desk-top equipment (incubator, luminometer and reader) required to run the test can be supplied.
The company, which has attracted government enterprise funding, is also interested in hearing from veterinary surgeons who might be interested in investing in the technology and helping to expand its use.
To place an order, contact James Turner, General Manager on 01638 501974, email: jamest@tandtreat.com or visit http://www.tandtreat.com.
Reference